Compare iShares MSCI Germany (DAX) (EWG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Germany (DAX) trades at $40.94 (market cap $1.52B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.5× iShares MSCI Germany (DAX)'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 55 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWG | TNGX | |
|---|---|---|
Market Cap | $1.52B | $3.75B |
Volume | 368,231 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $32.90 |
52-Week Low | $38.08 | $7.50 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.20 with a modest 0.59% daily gain, though technical indicators signal a bearish trend with moving averages showing 4 buy versus 9 sell signals. The stock faces resistance at $42 with support at $41. Recent European market focus highlights resilience amid ECB rate hikes and energy price pressures affecting regional equities.
Outlook remains cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on European economic stability, but risks include prolonged inflation and energy market volatility. Stock-specific fundamentals are unavailable, requiring deeper due diligence.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
